Biocomposites to present data on STIMULAN® and genex® at ECCMID 2022

Research findings from two studies demonstrate the antimicrobial effectiveness of STIMULAN® and genex®, when mixed with antibiotics Keele, UK, 12 April 2022,– Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the 32nd European […]

Adcendo – Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting

Copenhagen, Denmark, April 11th, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, is pleased to announce that a poster presentation will be provided on data of uPARAP targeting Antibody-Drug Conjugates in osteosarcoma preclinical xenograft models at the ongoing American Association […]

Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer

Deal value of up to US$525 million Novo Holdings co-led ReViral Series B financing in 2018 ReViral developing novel antiviral therapies to treat RSV infections Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its […]

eTheRNA Announces Relocation and Expansion of R&D Facility

GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium. The upgraded R&D facility is in the Zwijnaarde Science Park, where a […]

Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models

Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased survival in preclinical model of Alzheimer’s disease after administration of clinical molecule ASN90, as well as significant motor impairment and astrogliosis effect in a Parkinson’s model Unique functional benefits in gold-standard preclinical models of Alzheimer’s and Parkinson’s disease highlight the significant potential of O-GlcNAcase […]

© Optimum Strategic Communications.